L3VLUP
ProSign in

TECH · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TECHARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TECH
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterTECHARGX
Q3 202014 holders, $1.2bn8 holders, $3.6bn
Q4 202010 holders, $1.2bn7 holders, $4.1bn
Q1 202111 holders, $1.5bn8 holders, $4.1bn
Q2 20216 holders, $1.4bn9 holders, $4.6bn
Q3 20218 holders, $1.5bn8 holders, $4.5bn
Q4 20219 holders, $1.9bn9 holders, $5.3bn
Q1 20227 holders, $1.3bn8 holders, $5.3bn
Q2 202213 holders, $1.3bn13 holders, $6.5bn
Q3 202213 holders, $1.0bn14 holders, $5.3bn
Q4 20229 holders, $954m13 holders, $5.5bn
Q1 202315 holders, $896m13 holders, $5.9bn
Q2 202310 holders, $1.2bn18 holders, $6.6bn
Q3 202310 holders, $960m21 holders, $8.7bn
Q4 202310 holders, $1.2bn17 holders, $6.3bn
Q1 20248 holders, $1.2bn13 holders, $6.8bn
Q2 20247 holders, $1.4bn14 holders, $7.9bn
Q3 202410 holders, $2.1bn13 holders, $10.7bn
Q4 20248 holders, $1.7bn14 holders, $12.3bn
Q1 20258 holders, $1.2bn17 holders, $11.8bn
Q2 20258 holders, $860m18 holders, $10.8bn
Q3 202514 holders, $1.4bn16 holders, $13.8bn
Q4 202513 holders, $1.7bn16 holders, $14.8bn
Q1 202610 holders, $1.6bn11 holders, $12.3bn
Q2 202621 holders, $2.6bn14 holders, $15.0bn
TECH

Bio-techne Corp

Holders
8
Reported value
$1.2bn
Buyers
6
Sellers
3

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
17
Reported value
$11.8bn
Buyers
9
Sellers
9

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TECH (6)

Maverick Capital Ltd, MFS Investment Management, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC

Only ARGX (15)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Millennium Management LLC, Moore Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →